• Therapeutic Cataract & Refractive
  • Lens Technology
  • Glasses
  • Ptosis
  • Comprehensive Eye Exams
  • AMD
  • COVID-19
  • DME
  • Ocular Surface Disease
  • Optic Relief
  • Geographic Atrophy
  • Cornea
  • Conjunctivitis
  • Myopia
  • Presbyopia
  • Allergy
  • Nutrition
  • Pediatrics
  • Retina
  • Cataract
  • Contact Lenses
  • Lid and Lash
  • Dry Eye
  • Glaucoma
  • Refractive Surgery
  • Comanagement
  • Blepharitis
  • OCT
  • Patient Care
  • Diabetic Eye Disease
  • Technology

VUITY topline phase 3 results announced


Study evaluated twice-daily administration of VUITY (pilocarpine HCI ophthalmic solution) 1.25% in adults with age-related blurry near Vision

Allergan announced positive topline results from its ongoing VUITY trial, which evaluated the safety and efficacy of twice-daily VUITY for the treatment of mild to moderate presbyopia in adults.

In the VIRGO Phase 3 trial, 230 adults with presbyopia were randomly assigned to receive two drops of VUITY twice a day for 14 days.

The trial met its primary endpoint, which was improving near vision without compromising distance vision at hour 9 and 3 hours after the second drops, on day 14.

Additional details of the trial will be presented at medical congresses and submitted for approval of a twice-daily administration of VUITY in 2022.

The study also showed that a significant portion of participants gained 3 lines of vision.

The safety of the trial was similar to studies that have shown that once-daily administration of VUITY can improve near vision. However, the twice-daily use of VUITY is not approved by the FDA.

Related Videos
Jacob R. Lang, OD, FAAO
The ins and outs of fitting multifocal contact lenses with Dr Jessica Crooker
Patrick Mooney, CEO of SpyGlass Pharma
© 2024 MJH Life Sciences

All rights reserved.